CBD

DEA Officially Deschedules GW Pharma's CBD Epilepsy Treatment Epidiolex

DEA Officially Deschedules GW Pharma's CBD Epilepsy Treatment Epidiolex
Image credit: via Benzinga

Free Book Preview Cannabis Capital

Learn how to get your business funded in the Cannabis economy!
2 min read
Brought to you by Benzinga

GW Pharmaceuticals plc GWPH 7.76% confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance.

“This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act,” GW Pharma CEO Justin Gover said in a statement.

RELATED: What Does the 2018 Farm Bill Mean For Legal Cannabis?

Gover thanked the DEA for confirming "the non-controlled status" of the medicine.

"Importantly, the descheduling of EPIDIOLEX has the potential to further ease patient access to this important therapy for patients living with Lennox-Gastaut Syndrome and Dravet syndrome, two of the most debilitating forms of epilepsy," he said. 


Benzinga's #1 Breakout Stock Every Month

For over a decade, Benzinga has lead the way when it comes to investor access to information. Now Benzinga is about to do it all again with breakout stock recommendations. 

Led by Editor Gianni Di Poce, Benzinga Breakout Opportunity Letter uses three market-beating 'Delta Factors' to find stocks that could surge in the weeks ahead. Click here to find out how you can get the name of Benzinga's next breakout stock recommendation.


After obtaining the DEA notice, the Cambridge, U.K.-based company said it has filed a post-approval supplement with the FDA to lift the Schedule V designation from the drug. GW Pharma said it is now working on enforcing these amendments at the state level and via the Epidiolex distribution network.

Once all the changes have been enacted, the drug can be prescribed just like any other non-controlled medicine, with a prescription being valid for one year. 

RELATED: Consumers Reach For Cannabis To Calm Anxiety As COVID-19 Outbreak Continues

This allows doctors to prescribe the drug more freely, without the demands of state prescription drug monitoring programs, according to GW. 

GW Pharma shares were trading 4.66% higher at $90.62 at the time of publication Tuesday.

Related Links:

GW Pharma Vet Ethan Russo Launches Endocannabinoid Startup

GW Pharma Obtains Exclusive UK Commercialization Rights To Sativex From Bayer

Photo courtesy of GW Pharmaceuticals.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

More from Green Entrepreneur

Kim's expertise can help you become a strong leader, pitch VCs for capital, and develop a growth strategy.
Each week hear inspiring stories of business owners who have taken the cannabis challenge and are now navigating the exciting but unpredictable Green Rush.
Sign up for our weekly newsletter for winning strategies, exclusive features and all the tools you need to strike gold in the Green Rush.

Latest on Green Entrepreneur